MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3098
+0.0071
+2.35%
After Hours: 0.3100 +0.0002 +0.06% 19:58 12/04 EST
OPEN
0.3015
PREV CLOSE
0.3027
HIGH
0.3170
LOW
0.3000
VOLUME
11.90M
TURNOVER
--
52 WEEK HIGH
0.9577
52 WEEK LOW
0.1700
MARKET CAP
50.20M
P/E (TTM)
-18.2235
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ocugen (OCGN) Soars: Stock Adds 6.6% in Session
Ocugen (OCGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zacks · 2d ago
CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomys Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies
GlobeNewswire · 11/27 13:09
Ocugen (OCGN) Looks Good: Stock Adds 5.5% in Session
Ocugen (OCGN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zacks · 11/19 13:38
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.Below is a list of notable value stocks in the healthcare sector: 1. SELLAS Life Sciences Gr (NASDAQ: SLS) - P/E: 0.62 2. Supernus Pharmaceuticals (NASDAQ: SUPN) - P/E: 9.78 3. Ocugen (NASDAQ: OCGN) - P/E: 0.04 4. Oncternal Therapeutics (NASDAQ: ONCT) - P/E: 4.61 5. Coherus BioSciences (NASDAQ: CHRS) - P/E: 7.01SELLAS Life Sciences Gr has been featured as a value stock. SELLAS Life Sciences Gr's Q2 EPS sits at -0.66, which has not changed since last quarter (Q1). SELLAS Life Sciences Gr does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Supernus Pharmaceuticals reported earnings per share at 0.74, whereas in Q2 earnings per share sat at 0.65. Supernus Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Ocugen has reported Q3 earnings per share at -0.02, which has increased by 89.47% compared to Q2, which was -0.19. Ocugen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Oncternal Therapeutics reported earnings per share at -0.22, whereas in Q2 earnings per share sat at -0.34. Oncternal Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Coherus BioSciences's earnings per share for Q3 sits at 0.47, whereas in Q2, they were at 0.81. Coherus BioSciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.See more from Benzinga * Click here for options trades from Benzinga * 5 Value Stocks To Watch In The Real Estate Sector * Return On Capital Employed Overview: Pfizer(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/09 14:30
CEO Dr. Shankar Musunuri to Discuss the Importance of Gene Therapy Strategic Partnerships at 4th Annual Gene Therapy for Rare Disorders Europe Conference
MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on the importance of strategic partnerships in gene therapy including product consistency, identifying the right partner as well as providing examples of successful partnerships at the 4th Annual Gene Therapy for Rare Disorders Europe Conference from October 26-28, 2020 presented digitally. Presentation Details: Title:  “The Importance of Strategic Partnerships in Gene Therapy” Date: Wednesday, October 28, 2020 Time: 11:00 AM (GMT) Location: Digital Register: https://genetherapy-europe.com/take-part/register/About Ocugen, Inc. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com.Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.Corporate Contact: Ocugen, Inc. Sanjay Subramanian Chief Financial Officer IR@Ocugen.comMedia Contact: LaVoieHealthScience Katie Gallagher kgallagher@lavoiehealthscience.com +1 617-792-3937
GlobeNewswire · 10/22 11:30
Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen
MALVERN, Pa., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET. Ocugen management, including Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Sanjay Subramanian, CFO, Dr. Mohamed Genead, Acting CMO and Chair of the Scientific Advisory Board, and Dr. Mark Pennesi, Scientific Advisory Board Member, will discuss Ocugen’s lead program, OCU400 (AAV-NR2E3), a modifier gene therapy indicated for retinal degeneration disorders. In addition, they will provide highlights from the clinical, histological, and functional outcomes as published in Nature Gene Therapy evaluating AAV-NR2e3. They will also provide retina and disease backgrounds of members of the Retina Scientific Advisory Board. Lastly, they will provide an update on their goal of initiating two clinical trials in 2021 for OCU400 and expanding into four clinical trials in 2022 with OCU410 (AAV-RORA) for the treatment of dry age-related macular degeneration and OCU200, a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema, Diabetic Retinopathy, and Wet Age-Related Macular Degeneration.Cantor Fitzgerald initiated analyst coverage of Ocugen with an “Overweight” rating and a price target of $1.00 on October 9, based on its potential of AAV-based gene therapies and the belief that the eye is one of the most well understood target organs. All reports on Ocugen prepared by analysts represent the views of those analysts and not necessarily those of Ocugen. Ocugen is not responsible for the content, accuracy, or timing of analyst reports. A copy of the full analyst note can be obtained directly from Cantor Fitzgerald.Call Details: Cantor Fitzgerald Fireside Chat with Ocugen Date: Wednesday, October 21, 2020 Time: 11 AM (Eastern Time) Pre-Register for Call: https://us02web.zoom.us/webinar/register/WN_V3oYtzu5SwqMsoLgDvvqKAAbout Ocugen, Inc. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com.Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.Corporate Contact: Ocugen, Inc. Sanjay Subramanian Chief Financial Officer ir@ocugen.com Media Contact: LaVoieHealthScience Katie Gallagher kgallagher@lavoiehealthscience.com +1 617-792-3937
GlobeNewswire · 10/16 11:30
Opthea Readies Plan For U.S. IPO
Opthea has filed proposed terms to raise capital from a U.S. IPO.The firm is developing a treatment for Wet AMD and other eye conditions.OPT has produced impressive Phase 2b efficacy trial results for its lead candidate, so the IPO is worth considering for long-term hold life science investors.
Seekingalpha · 10/12 22:38
Overview Of Value Stocks In The Healthcare Sector
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Innoviva (NASDAQ: INVA) - P/E: 5.08 2. Jaguar Health (NASDAQ: JAGX) - P/E: 0.02 3. OpGen (NASDAQ: OPGN) - P/E: 2.94 4. Brookdale Senior Living (NYSE: BKD) - P/E: 6.09 5. Ocugen (NASDAQ: OCGN) - P/E: 0.05Innoviva saw an increase in earnings per share from 0.59 in Q1 to 0.69 now. Innoviva does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Jaguar Health reported earnings per share at -0.44, whereas in Q1 earnings per share sat at -0.56. Jaguar Health does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.OpGen has reported Q2 earnings per share at -0.49, which has decreased by 13.95% compared to Q1, which was -0.43. OpGen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Brookdale Senior Living experienced a decrease in earnings per share, which was 0.09 in Q1 and is now -0.65. Brookdale Senior Living does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Ocugen has reported Q2 earnings per share at -0.19, which has decreased by 171.43% compared to Q1, which was -0.07. Ocugen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Looking Into Twilio's Return On Capital Employed * 5 Value Stocks In The Real Estate Sector(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 10/12 14:19
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCGN. Analyze the recent business situations of Ocugen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCGN stock price target is 0.9000 with a high estimate of 1.000 and a low estimate of 0.7000.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 19.94M
% Owned: 12.30%
Shares Outstanding: 162.03M
TypeInstitutionsShares
Increased
9
12.12M
New
10
-737.72K
Decreased
1
98.84K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.23%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Chief Executive Officer/Director
Shankar Musunuri
Chief Financial Officer/Chief Accounting Officer/Treasurer
Sanjay Subramanian
Senior Vice President
Vijay Tammara
Chief Scientific Officer
Rasappa Arumugham
Vice President/Secretary/IR Contact Officer
Kelly Beck
Independent Director
Kirsten Castillo
Independent Director
Prabhavathi Fernandes
Independent Director
Uday Kompella
Independent Director
Ramesh Kumar
Independent Director
Manish Potti
Independent Director
Suha Taspolatoglu
Independent Director
Junge Zhang
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OCGN
Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ocugen Inc stock information, including NASDAQ:OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.